{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:48:55Z","timestamp":1792838935766,"version":"4.5.0"},"reference-count":155,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jhep.2021.09.042","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T17:56:23Z","timestamp":1634838983000},"page":"420-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies"],"prefix":"10.1016","volume":"76","author":[{"given":"J\u00e9r\u00e9my","family":"Dana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0345-963X","authenticated-orcid":false,"given":"Dominique","family":"Debray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Beaufr\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hillaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3081-2478","authenticated-orcid":false,"given":"Monique","family":"Fabre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Reinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureline","family":"Berteloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Vilgrain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.09.042_bib1","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.30148","article-title":"Cystic fibrosis liver\u00a0disease: outcomes and risk factors in a large cohort of French patients","volume":"69","author":"Bo\u00eblle","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jhep.2004.08.006","article-title":"Epidemiology of liver disease in cystic fibrosis: a longitudinal study","volume":"41","author":"Lamireau","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib3","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/lt.24842","article-title":"Liver transplantation in adult cystic fibrosis: clinical, imaging, and pathological evidence of obliterative portal venopathy","volume":"23","author":"Hillaire","year":"2017","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2021.09.042_bib4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/MPG.0000000000001676","article-title":"Cystic fibrosis-related liver disease: research challenges and future perspectives","volume":"65","author":"Debray","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib5","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome","volume":"36","author":"Colombo","year":"2002","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2021.09.042_bib6","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(11)60006-4","article-title":"Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease","volume":"10","author":"Debray","year":"2011","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.jhep.2021.09.042_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212779","article-title":"The emerging burden of liver disease in cystic fibrosis patients: a UK nationwide study","volume":"14","author":"Toledano","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.09.042_bib8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jhep.2011.03.028","article-title":"Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation","volume":"55","author":"Chryssostalis","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MPG.0000000000001728","article-title":"Variceal hemorrhage and adverse liver outcomes in patients with cystic fibrosis cirrhosis","volume":"66","author":"Ye","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.cgh.2016.03.041","article-title":"Features of severe liver disease with portal hypertension in patients with cystic fibrosis","volume":"14","author":"Stonebraker","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1432-2277.2006.00344.x","article-title":"Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry","volume":"19","author":"Melzi","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2021.09.042_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-8278(99)80166-4","article-title":"Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension","volume":"31","author":"Debray","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib13","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/0016-5085(93)91085-V","article-title":"Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells","volume":"105","author":"Cohn","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.042_bib14","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/hep.23810","article-title":"The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies","volume":"52","author":"Beuers","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1055\/s-2001-19030","article-title":"Cholangiocyte biology and cystic fibrosis liver disease","volume":"21","author":"Feranchak","year":"2001","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2021.09.042_bib16","first-page":"32","article-title":"Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria?","volume":"25","author":"Potter","year":"1997","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib17","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/hep4.1266","article-title":"Diet-induced dysbiosis and genetic background synergize with cystic fibrosis transmembrane conductance regulator deficiency to promote cholangiopathy in mice","volume":"2","author":"Debray","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2021.09.042_bib18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jcmgh.2019.04.013","article-title":"Pathophysiology of cystic fibrosis liver disease: a channelopathy leading to alterations in innate immunity and in microbiota","volume":"8","author":"Fiorotto","year":"2019","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib19","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/hep.28817","article-title":"The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity","volume":"64","author":"Fiorotto","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib20","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1053\/j.gastro.2011.06.052","article-title":"Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-\u03baB-mediated inflammatory response in mice","volume":"141","author":"Fiorotto","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.042_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116967","article-title":"Intestinal lesions are associated with altered intestinal microbiome and are more frequent in children and young adults with cystic fibrosis and cirrhosis","volume":"10","author":"Flass","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.09.042_bib22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib23","first-page":"631","article-title":"Small intestine bacterial overgrowth is frequent in cystic fibrosis: combined hydrogen and methane measurements are required for its detection","volume":"56","author":"Lisowska","year":"2009","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.jhep.2021.09.042_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.clnu.2014.04.004","article-title":"The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies","volume":"33","author":"Li","year":"2014","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib25","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2036.2004.02174.x","article-title":"Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration","volume":"20","author":"Bruzzese","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.09.042_bib26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/MPG.0b013e3181d1b013","article-title":"Evidence of intestinal inflammation in patients with cystic fibrosis","volume":"51","author":"Werlin","year":"2010","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00441-013-1734-3","article-title":"Disrupted tight junctions in the small intestine of cystic fibrosis mice","volume":"355","author":"De Lisle","year":"2014","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.jhep.2021.09.042_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jcf.2012.03.007","article-title":"Gut dysbiosis in cystic fibrosis","volume":"11","author":"Scanlan","year":"2012","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib29","first-page":"290","article-title":"Intestinal permeability in cystic fibrosis in relation to genotype","volume":"25","author":"Hallberg","year":"1997","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib30","first-page":"327","article-title":"Bile acids as hormones: the FXR-FGF15\/19\u00a0pathway","volume":"33","author":"Kliewer","year":"2015","journal-title":"DDI"},{"key":"10.1016\/j.jhep.2021.09.042_bib31","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.28000","article-title":"Stimulation of nuclear receptor peroxisome proliferator\u2013activated receptor-\u03b3 limits NF-\u03baB-dependent inflammation in mouse cystic fibrosis biliary epithelium","volume":"62","author":"Scirpo","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nm.2101","article-title":"Pharmacological correction of a defect in PPAR-\u03b3 signaling ameliorates disease severity in Cftr-deficient mice","volume":"16","author":"Harmon","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib33","doi-asserted-by":"crossref","first-page":"C1555","DOI":"10.1152\/ajpcell.1998.275.6.C1555","article-title":"Characterization of CFTR expression and chloride channel activity in human endothelia","volume":"275","author":"Tousson","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2021.09.042_bib34","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1378\/chest.12-1934","article-title":"Evidence of vascular endothelial dysfunction in young patients with cystic fibrosis","volume":"143","author":"Poore","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jhep.2021.09.042_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.thromres.2017.12.012","article-title":"Increased platelet activation occurs in cystic fibrosis patients and correlates to clinical status","volume":"162","author":"Lindberg","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jhep.2021.09.042_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/01.RES.0000252802.25497.b7","article-title":"Platelets as immune cells","volume":"100","author":"von Hundelshausen","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.jhep.2021.09.042_bib37","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1172\/JCI129635","article-title":"Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation","volume":"130","author":"Ortiz-Mu\u00f1oz","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2021.09.042_bib38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1164\/rccm.200508-1243PP","article-title":"The inflammatory role of platelets in cystic fibrosis","volume":"173","author":"O\u2019Sullivan","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib39","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1096\/fj.10-159921","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response","volume":"24","author":"Mattoscio","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.jhep.2021.09.042_bib40","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00261-2020","article-title":"Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype","volume":"57","author":"Declercq","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhep.2021.09.042_bib41","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1183\/09031936.00212511","article-title":"Increased arterial stiffness in children with cystic fibrosis","volume":"39","author":"Buehler","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhep.2021.09.042_bib42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1113\/jphysiol.2005.085019","article-title":"Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cl\u2212 transport of mouse aortic smooth muscle cells","volume":"568","author":"Robert","year":"2005","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.jhep.2021.09.042_bib43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3389\/fphys.2020.00879","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) in human lung microvascular endothelial cells controls oxidative stress, reactive oxygen-mediated cell signaling and inflammatory responses","volume":"11","author":"Khalaf","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.jhep.2021.09.042_bib44","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00408-017-0029-y","article-title":"Increased soluble VCAM-1 and normal P-selectin in cystic fibrosis: a cross-sectional study","volume":"195","author":"Nowak","year":"2017","journal-title":"Lung"},{"key":"10.1016\/j.jhep.2021.09.042_bib45","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bcp.2009.04.029","article-title":"Inflammatory cytokines in vascular dysfunction and vascular disease","volume":"78","author":"Sprague","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2021.09.042_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1538-7836.2004.00683.x","article-title":"Increased soluble CD40 ligand levels in cystic fibrosis","volume":"2","author":"Falco","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jhep.2021.09.042_bib47","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.bbadis.2017.08.011","article-title":"Mechanisms of endothelial cell dysfunction in cystic fibrosis","volume":"1863","author":"Totani","year":"2017","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"10.1016\/j.jhep.2021.09.042_bib48","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1055\/s-0037-1616736","article-title":"Endothelial perturbation in cystic fibrosis","volume":"86","author":"Romano","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jhep.2021.09.042_bib49","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jcf.2006.02.003","article-title":"Catheter-related thrombosis associated with elevated factor VIII levels in cystic fibrosis","volume":"5","author":"Serisier","year":"2006","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib50","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MCP.0000000000000428","article-title":"Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease","volume":"23","author":"van de Peppel","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib51","article-title":"Supersonic shear-wave elastography and APRI for the detection and staging of liver disease in pediatric cystic fibrosis","author":"Calvopina","year":"2019","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.jhep.2021.09.042_bib52","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.510300527","article-title":"Natural history of liver disease in cystic fibrosis","volume":"30","author":"Lindblad","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib53","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib54","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1046\/j.1523-1755.2000.00922.x","article-title":"Pharmacologic restoration of \u03b1\u03b4F508 CFTR-mediated chloride current","volume":"57","author":"Zeitlin","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2021.09.042_bib55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/jhep.2003.50403","article-title":"Risk factors for the development of cystic fibrosis related liver disease","volume":"38","author":"Slieker","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-018-0766-6","article-title":"Clinical expression of cystic fibrosis in a large cohort of Italian siblings","volume":"18","author":"Terlizzi","year":"2018","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib57","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/1096-8628(20010201)98:4<294::AID-AJMG1097>3.0.CO;2-K","article-title":"Liver expression in cystic fibrosis could be modulated by genetic factors different from the cystic fibrosis transmembrane regulator genotype","volume":"98","author":"Castaldo","year":"2001","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.jhep.2021.09.042_bib58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOG.0000000000000508","article-title":"Modifier genes in cystic fibrosis-related liver disease","volume":"35","author":"Debray","year":"2019","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhep.2021.09.042_bib59","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1001\/jama.2009.1295","article-title":"Genetic modifiers of liver disease in cystic fibrosis","volume":"302","author":"Bartlett","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2021.09.042_bib60","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/s41436-019-0449-6","article-title":"SERPINA1 Z allele is associated with cystic fibrosis liver disease","volume":"21","author":"Bo\u00eblle","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jcf.2016.08.002","article-title":"Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen","volume":"16","author":"Woodruff","year":"2017","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MPG.0000000000000758","article-title":"Increase of serum \u03b3-glutamyltransferase associated with development of cirrhotic cystic fibrosis liver disease","volume":"61","author":"Bodewes","year":"2015","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jcf.2007.08.001","article-title":"Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease","volume":"7","author":"Mueller-Abt","year":"2008","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.jhep.2021.09.042_bib64","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpeds.2019.12.033","article-title":"Heterogeneous liver on research ultrasound identifies children with cystic fibrosis at high risk of advanced liver disease: interim results of a prospective observational case-controlled study","volume":"219","author":"Siegel","year":"2020","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jhep.2021.09.042_bib65","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jpeds.2015.06.062","article-title":"Baseline ultrasound and clinical correlates in children with cystic fibrosis","volume":"167","author":"Leung","year":"2015","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jhep.2021.09.042_bib66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MPG.0000000000002413","article-title":"Liver ultrasound patterns in children with cystic fibrosis correlate with noninvasive tests of liver disease","volume":"69","author":"Ling","year":"2019","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1067\/S0022-3476(03)00329-9","article-title":"Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors","volume":"143","author":"Lenaerts","year":"2003","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.jhep.2021.09.042_bib68","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep.24014","article-title":"Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy","volume":"53","author":"Lewindon","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib69","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00330-019-06480-6","article-title":"Quantification of hepatic steatosis with ultrasound: promising role of attenuation imaging coefficient in a biopsy-proven cohort","volume":"30","author":"Dioguardi Burgio","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2021.09.042_bib70","article-title":"Evaluation of the hepatorenal B-mode ratio and the \u201ccontrolled attenuation parameter\u201d for the detection and grading of steatosis","author":"Moret","year":"2020","journal-title":"Ultraschall Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib71","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1148\/radiol.12120896","article-title":"Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis","volume":"267","author":"Tang","year":"2013","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2021.09.042_bib72","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/BF02079063","article-title":"Complications of percutaneous liver biopsy in infants and children","volume":"154","author":"Lachaux","year":"1995","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jhep.2021.09.042_bib73","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCP.0b013e32834b7f51","article-title":"Liver disease in cystic fibrosis","volume":"17","author":"Rowland","year":"2011","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib74","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.09.042_bib75","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jcf.2017.03.006","article-title":"Liver disease in cystic fibrosis presents as non-cirrhotic portal hypertension","volume":"16","author":"Witters","year":"2017","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib76","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178784","article-title":"Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: results from a prospective longitudinal cohort study","volume":"12","author":"Klotter","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.09.042_bib77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1155\/2015\/138530","article-title":"Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis","volume":"29","author":"Sadler","year":"2015","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib78","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.7150\/thno.18650","article-title":"Ultrasound elastography: review of techniques and clinical applications","volume":"7","author":"Sigrist","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.jhep.2021.09.042_bib79","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/j.cgh.2019.03.015","article-title":"Accuracy of transient elastography data combined with APRI in detection and staging of liver disease in pediatric patients with cystic fibrosis","volume":"17","author":"Lewindon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib80","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/liv.12113","article-title":"Utility of transient elastography in the non-invasive evaluation of cystic fibrosis liver disease","volume":"33","author":"Kitson","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.09.042_bib81","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MPG.0000000000001448","article-title":"Correlation of transient elastography with severity of cystic fibrosis-related liver disease","volume":"64","author":"Aqul","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib82","first-page":"1","article-title":"Cystic fibrosis and noninvasive liver fibrosis assessment methods in children","author":"Enaud","year":"2021","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jhep.2021.09.042_bib83","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jcf.2018.08.010","article-title":"Magnetic resonance elastography demonstrates elevated liver stiffness in cystic fibrosis patients","volume":"17","author":"Hayes","year":"2018","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.jhep.2021.09.042_bib84","doi-asserted-by":"crossref","DOI":"10.1097\/MOG.0000000000000624","article-title":"Hepatic manifestations of cystic fibrosis","author":"Dana","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.jhep.2021.09.042_bib85","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/jmri.23731","article-title":"Magnetic resonance elastography of liver: technique, analysis, and clinical applications","volume":"37","author":"Venkatesh","year":"2013","journal-title":"J\u00a0Magn Reson Imag"},{"key":"10.1016\/j.jhep.2021.09.042_bib86","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1148\/radiol.2016160589","article-title":"Spin-echo echo-planar imaging MR elastography versus gradient-echo MR elastography for assessment of liver stiffness in children and young adults suspected of having liver disease","volume":"282","author":"Serai","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2021.09.042_bib87","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00330-019-06478-0","article-title":"Comparison between ROI-based and volumetric measurements in quantifying heterogeneity of liver stiffness using MR elastography","volume":"30","author":"Rezvani Habibabadi","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2021.09.042_bib88","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ultrasmedbio.2015.11.011","article-title":"Longitudinal transient elastography measurements used in follow-up for patients with cystic fibrosis","volume":"42","author":"Van Biervliet","year":"2016","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jhep.2021.09.042_bib89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/apt.14488","article-title":"Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis","volume":"47","author":"Elkrief","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.09.042_bib90","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00247-016-3637-4","article-title":"Diagnosing native liver fibrosis and esophageal varices using liver and\u00a0spleen stiffness measurements in biliary atresia: a pilot study","volume":"46","author":"Tomita","year":"2016","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.jhep.2021.09.042_bib91","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/517369","article-title":"Hepatic and splenic acoustic radiation force impulse shear wave velocity elastography in children with liver disease associated with cystic fibrosis","volume":"2015","author":"Ca\u00f1as","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jhep.2021.09.042_bib92","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jcf.2011.04.004","article-title":"Transient elastography and portal hypertension in pediatric patients with cystic fibrosis Transient elastography and cystic fibrosis","volume":"10","author":"Malbrunot-Wagner","year":"2011","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.jhep.2021.09.042_bib93","first-page":"241","article-title":"Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases","volume":"2","author":"Oppenheimer","year":"1975","journal-title":"Perspect Pediatr Pathol"},{"key":"10.1016\/j.jhep.2021.09.042_bib94","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/hep.29217","article-title":"Adult-onset cystic fibrosis liver disease: diagnosis and characterization of an underappreciated entity","volume":"66","author":"Koh","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib95","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jcf.2012.12.013","article-title":"Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis","volume":"12","author":"Friedrich-Rust","year":"2013","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib96","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.20506","article-title":"Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C","volume":"41","author":"Ziol","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044930","article-title":"Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis","volume":"7","author":"Chon","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.09.042_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042139","article-title":"Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores","volume":"7","author":"Karlas","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.09.042_bib99","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00330-018-5650-5","article-title":"The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: a clinical observational cohort study","volume":"29","author":"Poetter-Lang","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jhep.2021.09.042_bib100","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.cgh.2018.10.046","article-title":"Obliterative portal venopathy without cirrhosis is prevalent in pediatric cystic fibrosis liver disease with portal hypertension","volume":"17","author":"Wu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib101","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/MPG.0b013e3182432034","article-title":"Transcriptional basis for hepatic fibrosis in cystic fibrosis\u2013associated liver disease","volume":"54","author":"Pereira","year":"2012","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib102","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1148\/radiol.2015150887","article-title":"Spleen size is significantly influenced by body height and sex: establishment of normal\u00a0values for spleen size at US with a cohort of 1200 healthy individuals","volume":"279","author":"Chow","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2021.09.042_bib103","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1148\/radiol.12111785","article-title":"Obliterative portal venopathy: findings at CT imaging","volume":"263","author":"Glatard","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jhep.2021.09.042_bib104","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/his.13738","article-title":"Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition","volume":"74","author":"Guido","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.jhep.2021.09.042_bib105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","article-title":"Porto-sinusoidal vascular disease: proposal and description of a novel entity","volume":"4","author":"De Gottardi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib106","doi-asserted-by":"crossref","first-page":"152833","DOI":"10.1016\/j.prp.2020.152833","article-title":"Nodular regenerative hyperplasia \u2013 an under-recognized vascular disorder of liver","volume":"216","author":"Bakshi","year":"2020","journal-title":"Pathol - Res Pract"},{"key":"10.1016\/j.jhep.2021.09.042_bib107","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib108","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jcf.2019.07.003","article-title":"Risk factors for adverse outcome in infancy in meconium ileus cystic fibrosis infants: a multicentre Italian study","volume":"18","author":"Padoan","year":"2019","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib109","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/adc.75.1.67","article-title":"Neonatal cholestasis as the presenting feature in cystic fibrosis","volume":"75","author":"Lykavieris","year":"1996","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jhep.2021.09.042_bib110","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jcf.2017.07.006","article-title":"Gallbladder and bile duct disease in Cystic Fibrosis","volume":"16","author":"Assis","year":"2017","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib111","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0168-8278(99)80259-1","article-title":"Sclerosing cholangitis in adults with cystic fibrosis: a magnetic resonance cholangiographic prospective study","volume":"30","author":"Durieu","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib112","first-page":"303","article-title":"Volume and emptying of the gallbladder in patients with cystic fibrosis","volume":"10","author":"Santamaria","year":"1990","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib113","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11894-005-0053-6","article-title":"The gallbladder and biliary tract in cystic fibrosis","volume":"7","author":"Curry","year":"2005","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.jhep.2021.09.042_bib114","unstructured":"Cystic Fibrosis Foundation Registry - Annual Data Report n.d."},{"key":"10.1016\/j.jhep.2021.09.042_bib115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/jnci\/djs481","article-title":"Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States","volume":"105","author":"Maisonneuve","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2021.09.042_bib116","first-page":"357","article-title":"The pathological changes in the liver in cystic fibrosis of the pancreas","volume":"93","author":"Craig","year":"1957","journal-title":"AMA J Dis Child"},{"key":"10.1016\/j.jhep.2021.09.042_bib117","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0676.1994.tb00004.x","article-title":"Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis","volume":"14","author":"Strandvik","year":"1994","journal-title":"Liver"},{"key":"10.1016\/j.jhep.2021.09.042_bib118","doi-asserted-by":"crossref","first-page":"G1150","DOI":"10.1152\/ajpgi.00456.2004","article-title":"Essential fatty acid deficiency in mice is associated with hepatic steatosis and secretion of large VLDL particles","volume":"288","author":"Werner","year":"2005","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"key":"10.1016\/j.jhep.2021.09.042_bib119","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1756283X11430859","article-title":"Secondary causes of nonalcoholic fatty liver disease","volume":"5","author":"Kneeman","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.jhep.2021.09.042_bib120","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/s-2008-1040717","article-title":"Cystic fibrosis: its influence on the liver, biliary tree, and bile salt metabolism","volume":"2","author":"Isenberg","year":"1982","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2021.09.042_bib121","first-page":"1737","article-title":"Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota","volume":"60","author":"Bernhard","year":"2021","journal-title":"Eur\u00a0J\u00a0Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib122","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/nu11030656","article-title":"Choline supplementation in cystic fibrosis\u2014the metabolic and clinical impact","volume":"11","author":"Bernhard","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.jhep.2021.09.042_bib123","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/ajcn\/81.3.686","article-title":"Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine","volume":"81","author":"Chen","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jhep.2021.09.042_bib124","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1590\/1984-0462\/;2019;37;4;00007","article-title":"Prevalence of hepatic steatosis among children and adolescents with cystic fibrosis and its association with nutritional status","volume":"37","author":"Gobato","year":"2019","journal-title":"Rev Paul Pediatr"},{"key":"10.1016\/j.jhep.2021.09.042_bib125","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hep.1840160215","article-title":"Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis","volume":"16","author":"Lindblad","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib126","series-title":"2019 patient Registry annual data report","first-page":"92","year":"2019"},{"key":"10.1016\/j.jhep.2021.09.042_bib127","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A\u00a0new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib128","article-title":"Ursodeoxycholic acid for cystic fibrosis-related liver disease","author":"Cheng","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2021.09.042_bib129","article-title":"Ursodeoxycholic acid and liver disease associated with cystic fibrosis: a multicenter cohort study","author":"Colombo","year":"2021","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib131","first-page":"288","article-title":"Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases","volume":"35","author":"Halilbasic","year":"2017","journal-title":"DDI"},{"key":"10.1016\/j.jhep.2021.09.042_bib132","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/lt.25421","article-title":"A\u00a0multidisciplinary approach to pretransplant and posttransplant management of cystic fibrosis\u2013associated liver disease","volume":"25","author":"Freeman","year":"2019","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2021.09.042_bib133","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/lt.22240","article-title":"Liver transplantation in patients with cystic fibrosis: analysis of united network for organ sharing data","volume":"17","author":"Mendizabal","year":"2011","journal-title":"Liver Transplant"},{"key":"10.1016\/j.jhep.2021.09.042_bib134","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jpedsurg.2019.01.035","article-title":"Cystic fibrosis and portal hypertension: distal splenorenal shunt can prevent the need for future liver transplant","volume":"54","author":"Lemoine","year":"2019","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.jhep.2021.09.042_bib135","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jcf.2020.06.019","article-title":"Transjugular intrahepatic portosystemic shunt in non-cirrhotic portal hypertension related to cystic fibrosis in a lung transplant patient","volume":"19","author":"Lupi","year":"2020","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib136","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib137","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib138","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of lumacaftor\u2013ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib139","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcf.2018.12.011","article-title":"Predictive factors for lumacaftor\/ivacaftor clinical response","volume":"18","author":"Masson","year":"2019","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib140","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib141","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2021.09.042_bib142","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jhep.2021.09.042_bib143","first-page":"P259","article-title":"Liver function tests in F508del homozygous paediatric patients with cystic fibrosis taking lumacaftor\/ivacaftor combination therapy","volume":"114","author":"Paluck","year":"2021","journal-title":"Irish Med J"},{"key":"10.1016\/j.jhep.2021.09.042_bib144","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","author":"Drummond","year":"2021","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib145","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v11.i12.761","article-title":"Lumacaftor\/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients","volume":"11","author":"Kutney","year":"2019","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib146","series-title":"Orkambi, summary of product characteristics","year":"2018"},{"key":"10.1016\/j.jhep.2021.09.042_bib147","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/hep.29400","article-title":"Src kinase inhibition reduces inflammatory and cytoskeletal changes in \u0394F508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy","volume":"67","author":"Fiorotto","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.042_bib148","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.09.042_bib149","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.042_bib150","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3389\/fphar.2019.01515","article-title":"Paracrine fibroblast growth factor 1 functions as potent therapeutic agent for intrahepatic cholestasis by downregulating synthesis of bile acid","volume":"10","author":"Lin","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jhep.2021.09.042_bib151","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature10998","article-title":"A\u00a0PPAR\u03b3\u2013FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis","volume":"485","author":"Jonker","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2021.09.042_bib152","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jsbmb.2016.11.001","article-title":"Role of vitamin D on gut microbiota in cystic fibrosis","volume":"175","author":"Kanhere","year":"2018","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"key":"10.1016\/j.jhep.2021.09.042_bib153","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jcf.2011.06.013","article-title":"Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis","volume":"10","author":"McNally","year":"2011","journal-title":"J\u00a0Cystic Fibrosis"},{"key":"10.1016\/j.jhep.2021.09.042_bib154","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1111\/bph.13249","article-title":"Down-regulation of IL-8 by high-dose vitamin D is specific to hyperinflammatory macrophages and involves mechanisms beyond up-regulation of DUSP1","volume":"172","author":"Dauletbaev","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jhep.2021.09.042_bib155","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.cell.2013.03.028","article-title":"A\u00a0vitamin D receptor\/SMAD genomic circuit gates hepatic fibrotic response","volume":"153","author":"Ding","year":"2013","journal-title":"Cell"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821021152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:44:37Z","timestamp":1759175077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821021152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":155,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0168827821021152"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.09.042","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.09.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}